Low dose immune checkpoint blockade in metastatic cancer
AssigneeLODOCO CLINICAL Kft.
InventorsTibor Bakács, Ralf Kleef
Life of this patent
Estimating the term…
Abstract
A method of treating cancer comprising and reducing autoimmune side effects in administration of anti-CTLA-4 antibodies. The invention provides methods for low dose immune checkpoint (IC) treatment of metastatic cancer by delivering anti-CTLA-4 and anti-PD-1 antibodies to cancer patients. Methods also provide for IL-2 stimulation for the activation of T cells against tumor cells. The invention further provides methods for daily cyclic high fever response (hyperthermia) during IL-2 therapy. The methods provide treatment of metastatic cancer without unacceptable autoimmune side effects.
Claims17
A method for reducing autoimmune side effects by administering an effective amount of anti-PD-1 antibody to a patient anticipating or experiencing anti-CTLA-4 autoimmune side effects or by administering an effective amount of anti-CTLA-4 antibody to a patient anticipating or experiencing anti-PD-1 autoimmune side effects.
A method for enhancing cancer immunity in a patient while reducing autoimmunity in said patient comprising administering anti-PD-1 antibody and anti-CTLA-4 antibody in effective amounts to a patient in need of treatment.
A composition for treating cancer comprising effective amounts of anti-PD-1 antibody and anti-CTLA-4 antibody, and at least one pharmaceutically acceptable excipient, wherein the amount of the antibodies in the composition is sufficient to produce a lower level of autoimmunity as compared to a composition of either antibody alone.
Dependencies are inferred from the claim text.